UK MedTech Strolll secures €5 million in Innovate UK funding and additional IW Capital-led investment

Strolll, a Stafford-based software-as-a-medical-device (SaMD) company using Augmented Reality for neurorehabilitation, has secured a new round of investment led by IW Capital, with participation from Cleveland Clinic and Future Planet Capital Regional.

Additionally, Innovate UK has separately provided the company with a €4.18 million (£3.6 million) innovation loan and an €813.2k (£700k) Growth Catalyst Investor Partnerships (GCIP) award. The two awards fund two distinct projects and together provide €5 million (£4.3 million) in funding for Strolll. In March 2025, the company raised a €12.2 million Series A funding round led by IW Capital.

Jorgen Ellis, CEO and co-founder of Strolll, said, “Our team is committed to revolutionising rehabilitation for those living with neurological disorders. This funding will help us accelerate our mission to increase patient engagement, support progression and help clinicians deliver effective neurorehabilitation to a wider patient population.”

Founded in 2018, Strolll is a MedTech startup that develops digital therapeutics software delivered via AR glasses to provide clinically proven and patented neurorehabilitation to patients living with neurological disorders. It supports therapy in both clinic and home settings. According to the company, the neurorehabilitation market is growing as more people need access to rehabilitation and ongoing support. Strolll claims that it is helping to meet this need through augmented reality, making rehabilitation more engaging and easier to access while helping clinicians support patients through their recovery.

The company has secured the €4.18 million (£3.6 million) Innovate UK innovation loan to accelerate the development of StrolllAssessment, a platform that combines AI with a fully equipped biomechanics lab that mirrors real-world rehabilitation settings. Strolll states that by enabling multiple validation studies to take place simultaneously, the platform could reduce a process that traditionally takes years to just months. And it can do so while providing a scalable, standards-compliant approach to validating automated clinical assessments. With this innovation loan, StrolllAssessment will extend the platform by using AI to automate the clinical validation of digital neuromotor assessments. The innovation loan will also support the company in establishing a fully equipped biomechanics lab at its office in Stafford, designed to mirror real-world rehabilitation settings and allow validation of multiple new digital assessments concurrently.

With the €813.2k (£700k) GCIP award and more than €1.16 million (£1 million) in investor funding, Strolll will introduce StrolllAcute, a bedside-first augmented reality rehabilitation system designed specifically for acute, bed-bound patients. It enables early therapeutic intervention without changing existing ward workflows or increasing staff burden.

Scott O’Brien, Chief Investment Officer at Innovate UK, said, “Across two innovations, Strolll has secured Innovate UK backing because it has proven both its technical excellence and a credible route to commercial success. De-risking later stage innovation through debt finance while providing grant alongside private capital demonstrates how Innovate UK is committed to providing the right product at the right time to accelerate innovation and fuel catalyse business growth.”

This investment provides Strolll with the backing to accelerate its continued growth and extend its product leadership.